Pixium Vision SA
PAR:ALPIX
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| FR |
|
Pixium Vision SA
PAR:ALPIX
|
1.5m EUR |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
192B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
174.6B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
136.5B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
131.8B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
112.1B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
59.8B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
46.4B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
51.6B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
45.4B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
39.5B USD |
Loading...
|
Market Distribution
| Min | -147 400% |
| 30th Percentile | -2.2% |
| Median | 2.6% |
| 70th Percentile | 7.1% |
| Max | 14 243.8% |
Other Profitability Ratios
Pixium Vision SA
Glance View
Pixium Vision SA conducts research and development on retinal implants. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2014-06-19. The firm is focused on the development of implantable medical devices for the treatment of blindness caused by degeneration of photoreceptor cells in the retina. The firm develops two Vision Restoration Systems (VRS) platforms, including IRIS and PRIMA. The Company’s implant technology replaces the signal processing functions in the retina by electrically stimulating the retinal cells, enabling them to transmit the stimulation signals to the brain’s visual cortex via the optic nerve, and its other systems initially enables patients with retinitis pigmentosa to partially recover their vision. The firm has collaboration with technology and academic institutions, including the Institut de la Vision (Paris), Universite Pierre et Marie Curie (Paris), Stanford University (the United States) and University of Ulm (Germany).
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Pixium Vision SA is -581.2%, which is in line with its 3-year median of -581.2%.
Over the last 3 years, Pixium Vision SA’s Net Margin has decreased from -414.6% to -581.2%. During this period, it reached a low of -581.5% on Jun 30, 2022 and a high of -411.7% on Dec 31, 2021.
